Related Experiment Videos
[Chemosensitivity test for bladder cancer in a nude-mice experimental system]
Hinyokika Kiyo. Acta Urologica Japonica
|December 1, 1986
Summary
In vivo chemosensitivity testing in nude mice accurately predicts patient response to bladder cancer chemotherapy. This method, using xenografts, guides effective treatment selection for individual patients.
Area of Science:
- Oncology
- Pharmacology
- Translational Medicine
Background:
- Establishing reliable in vivo models for bladder cancer chemosensitivity testing is crucial for personalized medicine.
- Comparing subcutaneous transplantation with the subrenal capsule assay (SRC) provides insights into optimal drug screening methodologies.
Observation:
- Human bladder cancer xenografts (BT-8, BT-11) and a carcinogen-induced strain (BBN-BT-1) in nude mice were used to evaluate drug efficacy.
- Chemosensitivity varied among drugs and strains; Cis-diamminedichloroplatinum(II) and 5-FU showed broad effectiveness.
- Drug efficacy was consistent between young and old xenograft strains, suggesting age is not a primary factor in sensitivity.
Findings:
- Cis-diamminedichloroplatinum(II) and 5-FU were effective against all tested bladder cancer xenograft strains.
- Specific drugs like adriamycin, cyclophosphamide, bleomycin, peplomycin, and vinca alkaloids demonstrated differential efficacy across strains.
- A patient's metastatic bladder cancer xenograft (BT-11) responded well to VPM-CisCF chemotherapy, validating the experimental model's clinical relevance.
Implications:
- In vivo chemosensitivity testing using xenografts in nude mice holds significant promise for guiding clinical treatment decisions in bladder cancer.
- The subrenal capsule assay (SRC) is recommended for individual primary tumor chemosensitivity testing, utilizing nude mice to mitigate immunoreactive rejection.
- These findings support the development of personalized chemotherapy regimens based on experimental drug sensitivity profiling.